A Randomized, Multi-Center, Single Masked, Sham Controlled, Proof-of-Concept Study of Intravitreal CLG561 as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy

Trial Profile

A Randomized, Multi-Center, Single Masked, Sham Controlled, Proof-of-Concept Study of Intravitreal CLG561 as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs CLG 561 (Primary) ; Tesidolumab (Primary)
  • Indications Dry macular degeneration
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Alcon
  • Most Recent Events

    • 04 Dec 2017 Status changed from active, no longer recruiting to completed.
    • 17 Apr 2017 Planned End Date changed from 1 Dec 2017 to 30 Nov 2017.
    • 13 Mar 2017 Planned End Date changed from 1 May 2018 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top